Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Research

SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022

Lauren E. Bloomfield, Sera Ngeh, Gemma Cadby, Kate Hutcheon, and Paul V. EfflerComments to Author 
Author affiliations: The University of Notre Dame Australia, Fremantle, Western Australia, Australia (L.E. Bloomfield); Western Australia Department of Health, East Perth, Western Australia, Australia (L.E. Bloomfield, S. Ngeh, G. Cadby, K. Hutcheon, P.V. Effler)

Main Article

Figure 5

Vaccine effectiveness against breakthrough infection of any severity, by time since booster vaccination, for homologous (all mRNA vaccines) versus heterologous (ChAdOx1 primary, mRNA booster) vaccination series, Western Australia, Australia, February 1–May 31, 2022. Error bars indicate 95% CIs.

Figure 5. Vaccine effectiveness against breakthrough infection of any severity, by time since booster vaccination, for homologous (all mRNA vaccines) versus heterologous (ChAdOx1 primary, mRNA booster) vaccination series, Western Australia, Australia, February 1–May 31, 2022. Error bars indicate 95% CIs.

Main Article

Page created: April 19, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external